| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 75781 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
79 |
WYQ |
2024-12-19 |
| 75782 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
70 |
kx |
2024-12-19 |
| 75783 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
91 |
wyh |
2024-12-19 |
| 75784 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
88 |
zyl |
2024-12-19 |
| 75785 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
95 |
wyh |
2024-12-19 |
| 75786 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
118 |
zyl |
2024-12-19 |
| 75787 |
Gly3-vc-PAB-MMAE， ADC试剂 |
103 |
kx |
2024-12-19 |
| 75788 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
87 |
WYQ |
2024-12-19 |
| 75789 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
104 |
wyh |
2024-12-19 |
| 75790 |
Azido-PEG4-Val-Ala-PAB-PNP |
99 |
zyl |
2024-12-19 |
| 75791 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
79 |
h |
2024-12-19 |
| 75792 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
89 |
wyh |
2024-12-19 |
| 75793 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
79 |
WYQ |
2024-12-19 |
| 75794 |
MC-PBD， ADC试剂 |
88 |
kx |
2024-12-19 |
| 75795 |
Mal-Val-Ala-PAB的介绍 |
90 |
zyl |
2024-12-19 |
| 75796 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
79 |
h |
2024-12-19 |
| 75797 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
84 |
WYQ |
2024-12-19 |
| 75798 |
Arm-DOTA-B72.3 |
79 |
h |
2024-12-19 |
| 75799 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
93 |
zyl |
2024-12-19 |
| 75800 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
126 |
h |
2024-12-19 |
| 75801 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
87 |
kx |
2024-12-19 |
| 75802 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
89 |
h |
2024-12-19 |
| 75803 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
111 |
WYQ |
2024-12-19 |
| 75804 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
124 |
zyl |
2024-12-19 |
| 75805 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
112 |
kx |
2024-12-19 |
| 75806 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
114 |
wyh |
2024-12-19 |
| 75807 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
78 |
h |
2024-12-19 |
| 75808 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
94 |
h |
2024-12-19 |
| 75809 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
114 |
wyh |
2024-12-19 |
| 75810 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
91 |
h |
2024-12-19 |
| 75811 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
124 |
WYQ |
2024-12-19 |
| 75812 |
1626359-62-3，SPDB-DM4， ADC试剂 |
81 |
kx |
2024-12-19 |
| 75813 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
88 |
WYQ |
2024-12-19 |
| 75814 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
110 |
wyh |
2024-12-19 |
| 75815 |
DOTA-(D)Phe(1)-Tyr(3) |
83 |
h |
2024-12-19 |
| 75816 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
124 |
zyl |
2024-12-19 |
| 75817 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
125 |
WYQ |
2024-12-19 |
| 75818 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
82 |
h |
2024-12-19 |
| 75819 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
95 |
WYQ |
2024-12-19 |
| 75820 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
114 |
wyh |
2024-12-19 |
| 75821 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
131 |
WYQ |
2024-12-19 |
| 75822 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
168 |
kx |
2024-12-19 |
| 75823 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
86 |
h |
2024-12-19 |
| 75824 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
96 |
wyh |
2024-12-19 |
| 75825 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
116 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询